InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.72
(
-0.15%
)
US TECH 100
19,223.20
(
-0.18%
)
Dow Jones
39,150.63
(
0.04%
)
Brent Oil
84.43
(
-0.68%
)
Bitcoin
64,255.18
(
-0.87%
)
Post# of 252299
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: jq1234 post# 122870

Tuesday, 07/05/2011 11:18:49 PM

Tuesday, July 05, 2011 11:18:49 PM

Post# of 252299

Roche Returns Development and Marketing Rights of SGLT2 Inhibitor CSG452 to Chugai

[Same class of drug as dapagliflozin. Roche has ended two diabetes drug development programs lately: GLP-1 taspoglutide and SGLT2 CSG452.]

LXRX's LX4211 is a dual SGLT2/SGLT1 inhibitor ( http://www.lexpharma.com/pipeline/lx4211.html ). I wonder if this news is bearish for their program as well, or maybe their drug is differentiated being a dual SGLT2/SGLT1 inhibitor.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up